Holen Sie sich die Stockscreener-App
46.45
0.24%
0.10
Schlusskurs vom Vortag:
$46.35
Offen:
$46.47
24-Stunden-Volumen:
722.93K
Relative Volume:
0.21
Marktkapitalisierung:
$19.90B
Einnahmen:
$2.38B
Nettoeinkommen (Verlust:
$1.32B
KGV:
26.09
EPS:
1.7806
Netto-Cashflow:
$897.24M
1W Leistung:
+1.87%
1M Leistung:
+0.55%
6M Leistung:
+31.70%
1J Leistung:
+48.11%
1-Tages-Spanne:
$46.10
$46.74
1-Wochen-Bereich:
$45.15
$47.54
52-Wochen-Spanne:
$29.66
$47.86
Royalty Pharma Plc Stock (RPRX) Company Profile
Firmenname
Royalty Pharma Plc
Sektor
Branche
Telefon
(212) 883-0200
Adresse
110 EAST 59TH STREET, NEW YORK, NY
Compare RPRX vs VRTX, REGN, ARGX, ALNY, INSM
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
RPRX
Royalty Pharma Plc
|
46.44 | 19.86B | 2.38B | 1.32B | 897.24M | 1.7806 |
VRTX
Vertex Pharmaceuticals Inc
|
440.46 | 110.01B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
750.14 | 77.99B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
703.05 | 42.91B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
318.82 | 42.09B | 3.71B | 313.75M | 465.38M | 2.2571 |
INSM
Insmed Inc
|
153.09 | 31.32B | 606.42M | -1.28B | -997.58M | -6.403 |
Royalty Pharma Plc Stock (RPRX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-01-30 | Hochstufung | UBS | Neutral → Buy |
| 2025-09-30 | Eingeleitet | Goldman | Buy |
| 2025-05-16 | Eingeleitet | Morgan Stanley | Overweight |
| 2024-06-03 | Herabstufung | UBS | Buy → Neutral |
| 2022-06-14 | Fortgesetzt | UBS | Buy |
| 2022-05-13 | Eingeleitet | Scotiabank | Sector Outperform |
| 2022-04-27 | Eingeleitet | Goldman | Buy |
| 2022-04-14 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2022-04-06 | Fortgesetzt | Morgan Stanley | Overweight |
| 2021-10-29 | Hochstufung | Citigroup | Neutral → Buy |
| 2021-07-30 | Eingeleitet | Tigress Financial | Buy |
| 2020-11-09 | Hochstufung | UBS | Neutral → Buy |
| 2020-07-14 | Eingeleitet | Evercore ISI | In-line |
| 2020-07-13 | Eingeleitet | BofA Securities | Buy |
| 2020-07-13 | Eingeleitet | Citigroup | Neutral |
| 2020-07-13 | Eingeleitet | Cowen | Outperform |
| 2020-07-13 | Eingeleitet | Goldman | Neutral |
| 2020-07-13 | Eingeleitet | JP Morgan | Neutral |
| 2020-07-13 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2020-07-13 | Eingeleitet | SunTrust | Buy |
| 2020-07-13 | Eingeleitet | UBS | Neutral |
Alle ansehen
Royalty Pharma Plc Aktie (RPRX) Neueste Nachrichten
Royalty Pharma commits $500M to J&J autoimmune drug development By Investing.com - Investing.com India
Royalty Pharma Announces R&D Funding Collaboration for Chronic Immune-Mediated Diseases - The Manila Times
Johnson & Johnson taps Royalty Pharma for $500M autoimmune drug push - Stock Titan
SG Americas Securities LLC Buys 234,629 Shares of Royalty Pharma PLC $RPRX - MarketBeat
Royalty Pharma PLC $RPRX Shares Sold by Cooper Investors PTY Ltd. - MarketBeat
Eastern Bank Acquires 263,867 Shares of Royalty Pharma PLC $RPRX - MarketBeat
Wedge Capital Management L L P NC Lowers Stock Position in Royalty Pharma PLC $RPRX - MarketBeat
Wealth Enhancement Advisory Services LLC Buys 165,451 Shares of Royalty Pharma PLC $RPRX - MarketBeat
Royalty Pharma PLC (NASDAQ:RPRX) Given Average Rating of "Buy" by Analysts - MarketBeat
Royalty Pharma PLC (NASDAQ:RPRX) Emerges as a Compelling Value Investment - ChartMill
Royalty Pharma (RPRX) Valuation Check As New AI And Deal-Making Leaders Take Charge - Sahm
Morgan Stanley Maintains a Buy Rating on Royalty Pharma Plc (RPRX) With a $55 PT - MSN
Royalty Pharma EVP Coyne sells shares worth $1.58 million By Investing.com - au.investing.com
Insider Selling: Royalty Pharma (NASDAQ:RPRX) CFO Sells 34,791 Shares of Stock - MarketBeat
Royalty Pharma EVP Coyne sells shares worth $1.58 million - Investing.com
Royalty Pharma (RPRX) CFO’s entities sell 34,791 shares under 10b5-1 plan - Stock Titan
Royalty Pharma (RPRX): Buy, Sell, or Hold Post Q4 Earnings? - Yahoo Finance
Nordea Investment Management AB Grows Position in Royalty Pharma PLC $RPRX - MarketBeat
How Royalty Pharma’s New AI and Dealmaking Hires Could Shape RPRX’s Royalty Sourcing Strategy - Sahm
Royalty Pharma names Lucas Glass as head of artificial intelligence By Investing.com - Investing.com India
Q4 Earnings Outperformers: Corcept (NASDAQ:CORT) And The Rest Of The Branded Pharmaceuticals Stocks - Yahoo Finance UK
Affiliates of RPRX sell multiple blocks of common stock (RPRX) - Stock Titan
Royalty Pharma plc Appoints Lucas Glass as Head of Artificial Intelligence, Effective April 2026 - marketscreener.com
Royalty Pharma names Lucas Glass as head of artificial intelligence - Investing.com
Royalty Pharma plc (RPRX) Latest Stock News & Headlines - Yahoo Finance
Royalty Pharma Appoints Lucas Glass as Head of Artificial Intelligence - The Globe and Mail
Royalty Pharma taps IQVIA tech executive to build AI across firm - Stock Titan
How The Royalty Pharma (RPRX) Story Is Shifting With New Deals And Updated Expectations - Yahoo Finance
UBS and Citi are bullish on Royalty Pharma plc (RPRX) – here’s why - MSN
(RPRX) Volatility Zones as Tactical Triggers - Stock Traders Daily
FOMO Trade: Will Royalty Pharma plc benefit from rate cuts2026 Setups & AI Optimized Trade Strategies - baoquankhu1.vn
Royalty Pharma PLC $RPRX Shares Purchased by Tudor Investment Corp ET AL - MarketBeat
S&P 500 Futures Decline In Premarket Trading; Super Micro Computer, Royalty Pharma Lag - Moomoo
S&P 500 Futures Decline in Premarket Trading; Super Micro Computer, Royalty Pharma Lag - Barron's
Aug Action: Does Royalty Pharma plc have high return on assets2026 Institutional & Daily Risk Controlled Trade Plans - baoquankhu1.vn
Does Royalty Pharma plc have high return on assets2026 Institutional & Daily Risk Controlled Trade Plans - baoquankhu1.vn
Royalty Pharma PLC $RPRX Stock Position Raised by JPMorgan Chase & Co. - MarketBeat
Royalty Pharma acquires royalty interest in Alnylam’s AMVUTTRA for $310M - MSN
RPRX: Entities report multi‑date sell notices including 136,980‑share trade - Stock Titan
Royalty Pharma plc (RPRX) earns $51 target as 2026 growth outlook exceeds expectations - MSN
[144] Royalty Pharma plc SEC Filing - Stock Titan
Revolution Medicines To Get Up To $2B For Development Of Cancer Drug From Royalty Pharma - MSN
54,266 Shares in Royalty Pharma PLC $RPRX Acquired by WBI Investments LLC - MarketBeat
ROYALTY PHARMA PLC-CL A (NASDAQ:RPRX) Shows High Technical and Setup Ratings Ahead of Potential Breakout - ChartMill
Royalty Pharma names Greg Butz as EVP of partnering, investments By Investing.com - Investing.com South Africa
Royalty Pharma plc (RPRXN.MX) Stock Price, News, Quote & History - Yahoo Finance
Royalty Pharma Announces Expansion of Leadership Team - The Manila Times
Royalty Pharma hires Bank of America healthcare banking executive - StreetInsider
Royalty Pharma PLC $RPRX Shares Bought by L2 Asset Management LLC - MarketBeat
Royalty Pharma Plc Experiences Valuation Adjustment Amid Strong Market Performance Metrics - Markets Mojo
Dorsey Asset Management LLC Buys Shares of 2,350,449 Royalty Pharma PLC $RPRX - MarketBeat
Finanzdaten der Royalty Pharma Plc-Aktie (RPRX)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.79%
0.80%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):